港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批_老虎社区_美港股上老虎

港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批

智通财经05-19

智通财经APP获悉，宜明昂科-B(01541)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α（IMM0306），在原发性干燥综合征（pSS）适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2636833670?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-19 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636833670","market":"us","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α（IMM0306），在原发性干燥综合征（pSS）适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1443375.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-19 15:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1443375.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α（IMM0306），在原发性干燥综合征（pSS）适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1443375.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1443375.html","article_id":"2636833670","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636833670","pubTimestamp":1779175568,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α，在原发性干燥综合征适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是宜明昂科“自免管线全面推进”战略的又一重要成果。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","01541":"宜明昂科-B","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"Hong Kong stock changes | Yiming Angke-B (01541) rose more than 6% in late trading IMM0306 primary Sjogren's syndrome IND application was officially approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"IND":1.5,"01541":1.5},"content_text":"智通财经APP获悉，宜明昂科-B(01541)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α（IMM0306），在原发性干燥综合征（pSS）适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是宜明昂科“自免管线全面推进”战略的又一重要成果。IMM0306的系统性红斑狼疮（SLE）、IgG4相关疾病（IgG4-RD）等多个重磅适应症的临床研究稳步推进中，SLE的Ib期临床数据将于2026 EULAR会议中展出。近年来，依托“mAb-Trap”技术平台的强大延展性，宜明昂科在自身免疫性疾病领域构建了丰富且具深度的产品管线。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}